Ailte I, Chauhan SK, Prasmickaite L, Bassarova AV, Poissonnier A, Feenstra M, Nyakas M, Johannessen B, Ryder T, Hermann R, Frich L, Holth A, Inderberg EM, Jespersen H, Flørenes VA, Kyte JA, Mælandsmo GM, Egeland EV(2026) CD38hiCD19dim cells in lymph nodes predict favorable prognosis in patients with stage III melanoma receiving adjuvant PD-1-blockade Front Oncol, 16, 1815008 DOI 10.3389/fonc.2026.1815008, PubMed 42158424
Ejder P, Jespersen H, Hernberg M, Ny L, Carneiro A, Ellegård S, Mattila K, Bagge RO, Fountoukidis G, Brandberg Y, Mandala M, O Carrigan B, Schilling B, Aranche A, Hamid O, Berglund A, Helgadottir H, Ullenhag G(2026) Grand SLAM study protocol: a prospective randomised multicentre study of shortened versus standard duration adjuvant immune checkpoint inhibition for stage IIB-C, III and IV cutaneous melanoma BMC Cancer, 26(1) DOI 10.1186/s12885-026-15924-4, PubMed 41896823
Giorcelli A, Valberg M, Green AC, Veierød MB, Costa DR, Gran JM, Svendsen HL, Jespersen H, Andreassen BK, Robsahm TE, Ghiasvand R(2026) Risk of recurrence of stage I to III melanoma in Norway, 2008-2022 Eur J Cancer, 245, 116940 DOI 10.1016/j.ejca.2026.116940, PubMed 42475979
